biomedicina slovenica

"Maligni mezoteliom" : 46

  1. Pezzuto Federica; Lunardi Francesca; Vedovelli Luca; Fortarezza Francesco; Urso Loredana; Grosso Federica; Ceresoli Giovanni Luca; Kern Izidor; Vlačić Gregor; Calabrese Fiorella
    P14/ARF-positive malignant pleural mesothelioma
    2022 ►
  2. Goričar Katja; Holcar Marija; Mavec Nina; Kovač Viljem; Lenassi Metka; Dolžan Vita
    Extracellular vesicle enriched miRNAs as prognostic biomarkers in malignant mesothelioma
    2021 ►
  3. Zupanc Cita; Franko Alenka; Štrbac Danijela; Dodič-Fikfak Metoda; Kovač Viljem; Dolžan Vita; Goričar Katja
    Serum calretinin as a biomarker in malignant mesothelioma
    2021 ►
  4. Štrbac Danijela; Goričar Katja; Dolžan Vita; Kovač Viljem
    Genetski označevalci pri mezoteliomu
    2021 ►
  5. Dolžan Vita; Švarc Miha; Goričar Katja; Štrbac Danijela; Kovač Viljem
    Uptake and efflux transporter polymorphisms influence cisplatin treatment outcome in malignant mesothelioma patients
    2021 ►
  6. Franko Alenka; Goričar Katja; Dodič-Fikfak Metoda; Kovač Viljem; Dolžan Vita
    The role of polymorpisms in glutathionerelated genes in asbestos-related diseases
    2021 ►
  7. Piber Petra; Vavpetič Neža; Goričar Katja; Franko Alenka; Dolžan Vita
    Genetska variabilnost mehanizmov uravnavanja izražanja IL-1[beta] in tveganje za nastanek malignega mezotelioma in plevralnih plakov
    2020 ►
  8. Bavec Maj; Prašnikar Marjeta; Goričar Katja
    Vpliv genetske variabilnosti glutation S-transferazna tveganje za pojav malignega mezotelioma
    2020 ►
  9. Piber Petra; Vavpetič Neža; Goričar Katja; Dolžan Vita; Kovač Viljem; Franko Alenka
    The influence of genetic variability in IL1B and MIR146A on the risk of pleural plaques and malignant mesothelioma
    2020 ►
  10. Brčić Luka; Kern Izidor
    Clinical significance of histologic subtyping of malignant pleural mesothelioma
    2020 ►
  11. Franko Alenka; Dolžan Vita; Goričar Katja; Dodič-Fikfak Metoda
    Asbestos-related diseases and blood biomarkers
    2020 ►
  12. Otsuki Takemi
    Asbestos-related diseases
    2020 ►
  13. Dolžan Vita; Franko Alenka
    Asbestos-related pleural diseases
    2020 ►
  14. Goričar Katja; Kovač Viljem; Dodič-Fikfak Metoda; Dolžan Vita; Franko Alenka
    Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases
    2020 ►
  15. Štrbac Danijela; Goričar Katja; Dolžan Vita; Kovač Viljem
    Evaluation of matrix metalloproteinase 9 serum concentration as a biomarker in malignant mesothelioma
    2019 ►
  16. Goričar Katja; Holcar Marija; Mavec Nina; Dodič-Fikfak Metoda; Franko Alenka; Kovač Viljem; Lenassi Metka; Dolžan Vita
    MicroRNAs in extracellular vesicles as biomarkers in malignant mesothelioma
    2019 ►
  17. Levpušček Kristina; Goričar Katja; Kovač Viljem; Dolžan Vita; Franko Alenka
    The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma
    2019 ►
  18. Šenk Barbara; Goričar Katja; Kovač Viljem; Dolžan Vita; Franko Alenka
    Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment
    2019 ►
  19. Kotnik Nika; Franko Alenka; Dolžan Vita; Goričar Katja; Dodič-Fikfak Metoda
    The influence of the polymorphisms of the DNA repair mechanisms on the risk of malignant mesothelioma
    2017 ►
  20. Goričar Katja; Kovač Viljem; Dolžan Vita
    Immune checkpoints PD-1 and PD-L1 polymorphisms and outcome of cisplatin-based chemotherapy in malignant mesothelioma
    2018 ►
  21. Dolžan Vita; Goričar Katja; Kovač Viljem
    Genetic polymorphisms of PD-L1 may influence response to platinum-based chemotherapy in malignant mesothelioma
    2018 ►
  22. Franko Alenka; Kotnik Nika; Goričar Katja; Kovač Viljem; Dodič-Fikfak Metoda; Dolžan Vita
    The influence of genetic variability on the risk of developing malignant mesothelioma
    2018 ►
  23. Goričar Katja; Kovač Viljem; Dolžan Vita
    Immune checkpoints PD-1 and PD-L1 polymorphisms and chemotherapy outcome in malignant mesothelioma
    2017 ►
  24. Goričar Katja; Kovač Viljem; Dolžan Vita
    The influence of PD-1 and PD-L1 polymorphisms on cisplatin-related toxicity in malignant mesothelioma
    2017 ►
  25. Goričar Katja; Kovač Viljem; Dolžan Vita
    Clinical-pharmacogenetic models for personalized cancer treatment
    2017 ►
  26. Goričar Katja; Kovač Viljem; Dolžan Vita
    Could clinical-pharmacogenetic models facilitate treatment selection in malignant mesothelioma?
    2016 ►
  27. Goričar Katja; Kovač Viljem; Dolžan Vita
    Facilitating treatment selection in malignant mesothelioma using clinical -pharmacogenetic models
    2016 ►
  28. Goričar Katja; Kovač Viljem; Dolžan Vita
    Clinical-pharmacogenetic model predicting treatment outcome in malignant mesothelioma
    2016 ►
  29. Goričar Katja; Kovač Viljem; Franko Alenka; Dodič-Fikfak Metoda; Dolžan Vita
    Serum survivin levels and outcome of chemotherapy in patients with malignant mesothelioma
    2015 ►
  30. Goričar Katja; Kovač Viljem; Dolžan Vita
    Polymorphisms in translesion polymerase genes and outcome of malignant mesothelioma treatment
    2013 ►
  31. Goričar Katja; Kovač Viljem; Dolžan Vita
    The influence of polymorphisms in folate pathway genes on pemetrexed treatment outcome in malignant mesothelioma patients
    2013 ►
  32. Jerše Maja
    Diffuse malignant mesothelioma
    [(Mesothelioma malignant diffusum)]
    2013 ►
  33. Rajer Mirjana
    Maligni mezoteliom
    2010 ►
  34. Goričar Katja; Kovač Viljem; Dolžan Vita
    Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma
    2014 ►
  35. Jeruc Jera; Kladnik Jene Marjeta; Pušelja Miha
    Malignant mesothelioma of the tunica vaginalis testis
    2014 ►
  36. Goričar Katja; Dolžan Vita
    Farmakogenetski označevalci odgovora na zdravljenje z analogi folne kisline in spojinami platine pri osteosarkomu in malignem mezoteliomu
    [Pharmacogenetic markers of response to treatmant with folic acid analogues and platinum compounds in osteosarcoma and malignant mesothelioma]
    2014 ►
  37. Kovač Viljem
    Maligni mezoteliom
    2014 ►
  38. Kovač Viljem
    Maligni mezoteliom - pojavnost v Sloveniji in pristopi k zdravljenju
    2013 ►
  39. Dodič-Fikfak Metoda; Franko Alenka
    Spremljanje incidence malignega mezotelioma z uporabo GIS
    [The follow-up of incidence of malignant mesothelioma using GIS]
    2013 ►
  40. Goričar Katja; Kovač Viljem; Dolžan Vita
    Polymorphisms in translesion polymerases influence treatment outcome in malignant mesothelioma
    2013 ►
  41. Goričar Katja; Kovač Viljem; Dolžan Vita
    #The #influence of polymorphisms in transporter coding genes on permetrexed treatment outcome in malignant mesothelioma patients
    2013 ►
  42. Dolžan Vita; Franko Alenka; Dodič-Fikfak Metoda; Kovač Viljem
    Molecular biomarkers of treatment response in malignant mesothelioma
    2013 ►
  43. Kovač Viljem
    Novosti v zdravljenju pljučnega raka ASCO, Chicago, 1.-5. junij 2012
    2012 ►
  44. Kovač Viljem
    Mezoteliomi
    2012 ►
  45. Edelbaher Natalija; Varga Tomaž
    Maligni mezoteliom - prikaz primera
    [Malignant mesothelioma - case report]
    2006 ►
  46. Mandelc-Grom Majda
    Poklicne bolezni zaradi izpostavljenosti azbestu v Sloveniji
    [Occupational diseases due to asbestos exposure in Slovenia]
    2001 ►


New search      Comments      Top of page Institute for Biostatistics and Medical Informatics